Price
$4.76+167.42%Social Signal Score
Analyst Ratings
9 analystsRevenue
$48.25M+328.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John T. Treace
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 450
- Beta
- 1.56
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.23
Financials
Revenue
$48.25M+328.7%Net Income
$-12.57MEBITDA
$-11.53MFree Cash Flow
$-5.42MEPS (diluted)
$-0.19Shares Outstanding (diluted)
65.46M+49.1%Operating Expenses
$49.88MCash & Debt
$39.80MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $212.69M | $-59.00M | $-0.93 |
| 2024 | $209.36M | $-55.74M | $-0.90 |
| 2023 | $187.12M | $-49.53M | $-0.81 |
| 2022 | $141.84M | $-42.81M | $-0.77 |
| 2021 | $94.42M | $-20.55M | $-0.38 |
| 2020 | $57.37M | $-3.67M | $-0.08 |
| 2019 | $39.42M | $-4.26M | $-0.10 |
Valuation
TMCIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
146+192.00%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·16d ago·Neutral
Treace Medical Concepts, Inc. (TMCI) Q3 2026 Earnings Call Transcript Treace Medical Concepts, Inc. ( TMCI ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentatio…
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call Treace Medical Concepts NASDAQ: TMCI reported a 4% decline in third-quarter revenue as a shift toward lower-priced products and lower bunion procedure kit sales offset growth in procedure volumes. The company narrowed its full-year revenue outlook and said it expects to return to growth in the fourth quarter.
View source ↗ - Newszacks.com·16d ago·Negative
Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.26 per share a year ago.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Treace Medical Concepts Reports Third Quarter 2026 Financial Results PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor's Bunion Correction System New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
… 2026 Financial Results on November 6, 2026 PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss fin…
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
…tive Outcomes of the Lapiplasty® Procedure PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations includ…
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies
View source ↗ - Newsseekingalpha.com·107d ago·Positive
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Fri, Feb 26(in 3 months)
Consensus estimate $-0.06 per share
Typical surprise +19.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$-0.19 vs $-0.25beat
- Fri, Aug 7$-0.24 vs $-0.30beat
- Fri, May 8$-0.28 vs $-0.31beat
- Fri, Feb 27$-0.12 vs $-0.15beat
- Thu, Nov 6$-0.26 vs $-0.28beat
- Thu, Aug 7$-0.28 vs $-0.29beat
Estimates and results for TMCI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TMCI officers and directors.
- Bought
- $2.0m
- Sold
- $398k
15 trades
1 trade
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·11,000 @ $4.34·$48k·Aug 24, 2026·filing
- Treace John T.bought
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·39,944 @ $4.44·$177k·Aug 20, 2026·filing
- Treace John T.bought
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·22,887 @ $4.04·$93k·Jun 11, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·14,715 @ $4.02·$59k·Jun 10, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·29,430 @ $4.02·$118k·Jun 10, 2026·filing
- Treace John T.boughtdirector, 10 percent owner, officer: Chief Executive Officer·50,000 @ $3.56·$178k·Jun 1, 2026·filing
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TMCI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
